Why the study?
Does TEVAR prevent aortic complications and death in patients with acute or subacute uncomplicated type B aortic dissection compared to medical management?
Does TEVAR prevent aortic complications and death in patients with acute or subacute uncomplicated type B aortic dissection compared to medical management?
Answers are grounded in this paper and cite their sources.
Routine TEVAR should not be offered for uncomplicated acute or subacute type B aortic dissection due to a lack of compelling evidence demonstrating superiority over medical management.
A brief search of conference abstracts and proceedings, editorials, and opinion pieces from the vascular community over the past decade has revealed exhaustive discussion of the indications for thoracic endovascular repair (TEVAR) of acute uncomplicated type B aortic dissection, specifically regarding the timing of intervention. The conversation appears to be perpetuated by an absence of new evidence supporting the routine adoption of this practice, which is mainly predicated by expert opinion and ultimately recursive to the same limited pool of literature. The accepted narrative is that acute uncomplicated dissections can be safely managed medically, but over time the chronically dissected aorta tends to degenerate, increasing the risk of aortic complications and death. Early TEVAR for uncomplicated dissection is safe in the short term, and promotes remodelling when performed in the early phase owing to the greater plasticity of the dissection flap, thus offering increased protection against aorta-related death1. Intuitively, this seems plausible, but the evidence on which to adopt such an approach is largely circumstantial and not enough to change clinical practice. Medical management is effective in preventing aneurysmal degeneration and other complications directly contributing to aorta-related death. Data from the International Registry of Acute Aortic Dissection (IRAD)2, a key repository of data on aortic dissection, suggests that there is no benefit in long-term outcomes from the addition of TEVAR to medical therapy, and the evidence is that any excess mortality may not actually be related to aortic degeneration3. A large single-centre study4 showed no difference in 5-year outcomes for patients with acute complicated dissection treated with TEVAR, medical treatment, and open surgery if the initial mortality ‘hit’ of the acute event was considered. The same study found that two-thirds of patients with medically managed uncomplicated dissection were alive after 10 years4. A contemporary systematic review5 of 17 studies concluded that TEVAR did not prevent late aneurysmal dilatation after dissection. Considering this, what are the current recommendations for clinical practice? The clinical guidelines issued by the European Society of Vascular Surgery6 are worded cautiously. Recommendation 18 states that ‘to prevent aortic complications in uncomplicated acute type B dissection, early thoracic endografting may be considered selectively’ (evidence level IIb B). The sole citation supporting this recommendation is the ADSORB trial7, which randomized 61 patients with acute uncomplicated type B dissection to receive best medical therapy (BMT) alone or BMT and TEVAR. Over 50 per cent of patients logged for randomization were included, but there was no indication of how many patients were screened for inclusion as ‘no logbook was filled out’. There was no difference in aortic dilatation or death between the two groups, only in the proportion of those who displayed incomplete false-lumen thrombosis, which was the only endpoint designed to quantify aortic remodelling. All of the patients in the BMT group failed this endpoint versus half in the TEVAR group, although it should be noted that 14 of 61 follow-up scans (23 per cent) were missing, and these patients were counted as a clinical failure regarding this endpoint. Based on these data, the composite endpoint favoured TEVAR and BMT over BMT alone. Comparing a weak surrogate endpoint, such as false-lumen thrombosis, with no or uncertain clinical implications, should not be used to inform changes in clinical practice. Furthermore, its use could be considered invalid, given that thrombosis of the false lumen in the TEVAR group was ubiquitous, and in medically managed patients is well known to be highly unlikely. The study was due to report 3-year outcomes, which have yet to be published. The assertion that this study showed evidence of greater aortic remodelling in the TEVAR group does not stand up to scrutiny. Recommendation 39 of the European Society of Vascular Surgery guidelines is that patients at further risk of aortic complications with chronic type B dissections and suitable anatomy should undergo TEVAR in the subacute phase (level IIb B). This recommendation has one citation, the INSTEAD trial8, which compared outcomes of BMT alone with those of TEVAR and BMT for patients with chronic or subacute dissections for 5 years. In this study, 597 patients were screened and 140 were randomized. Interestingly, some 293 patients refused randomization into the trial, preferring standard medical therapy, which may give an indication of patient preference among those with this condition. Although there was no difference in all-cause mortality, probably because of the better-than-expected 80.7 per cent 5-year survival rate in the BMT group, the TEVAR group had improved aorta-related survival at follow-up (P = 0.045). A vitally important observation was that all the patients with aortic rupture in the BMT group had a large-diameter entry tear of over 10 mm, a finding that was also present in the group that crossed over to require intervention later during follow-up. This perhaps suggests that, rather than being used routinely, TEVAR should be applied only to specific high-risk subgroups of acute or subacute dissection. Worryingly, the patients with aortic rupture who died in this study underwent stringent follow-up and imaging surveillance, but still seemed subject to unheralded catastrophic events. It could be that the surgeons of these patients failed to intervene in the chronic phase of the dissection, either because the signs of impending events were underappreciated, the threshold for treatment was too high, or because the patients had disease that was too complex to treat. Developments in endovascular aortic surgery since this trial was reported have provided options for patients with chronic dissection related aneurysmal disease. TEVAR for acute uncomplicated dissection seems to be safe in the short term, with low rates of retrograde aortic dissection and good periprocedural outcomes1. Despite this, it is well known that the risk of stroke, paraplegia, and significant cardiac and renal complications exists. These can affect long-term health and quality of life, even if they do not cause a hard endpoint such as death. Even so, periprocedural safety is not a justification for routine intervention if it is not effective in preventing later aortic complications by some observable mechanism. Selected patients probably benefit from early TEVAR, but there is a lack of robust evidence to define this group at present, and it likely to represent a minority of patients. Several potential risk factors for subsequent degeneration of the aorta have been postulated and used to propose stratification methods, but dissection is a morphologically heterogeneous disease which makes detailed study of subgroups very challenging9. Furthermore, no robust analysis of the health economic benefit of early TEVAR versus observation and medical management has been conducted. In the absence of any compelling evidence to the contrary, TEVAR should not be offered routinely to patients with uncomplicated acute or subacute dissection. Intensive early medical management and imaging surveillance should be employed to identify those most likely to benefit based on early unfavourable dynamic morphology, appropriate anatomy for treatment, and good predicted longevity. Disclosure. The authors declare no conflict of interest.
No takes yet. Share an insight, caveat, or question.
Benjamin O. Patterson (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: